<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2020-04610-998-12262</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">New organometallic antimalarials</narrative>
   <narrative xml:lang="SV">Nya metallorganiska antimalarial&#xE4;kemedel</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Malaria &#xE4;r en mycket spridd sjukdom som s&#xE4;rskilt drabbar utvecklingsl&#xE4;nder och d&#xE4;r orsakar samh&#xE4;lleliga skador som f&#xF6;rsv&#xE5;rar l&#xE4;ndernas utveckling. Situationen &#xE4;r s&#xE4;rskilt allvarlig f&#xF6;r afrikanska l&#xE4;nder s&#xF6;der om Sahara. &#xC4;ven om mycket stora framsteg har gjorts vad g&#xE4;ller f&#xF6;rebyggande och behandling&#xA0;av malaria, finns det ett stort behov av kontinuerlig utveckling av nya l&#xE4;kemedel f&#xF6;r behandling av denna sjukdom.&#xA0;Anledningen &#xE4;r&#xA0;att malariaparasiter relativt snabbt utvecklar resistens mot l&#xE4;kemedel. I detta forskningsprojekt unders&#xF6;ks m&#xF6;jligheten att metallkomplex kan h&#xE4;mma malaria, med syftet att s&#xE5;dana metallkomplex skall kunna anv&#xE4;ndas som l&#xE4;kemedel. De metallkomplex som framst&#xE4;lls inneh&#xE5;ller k&#xE4;nda eller postulerade aktiva fragment fr&#xE5;n etablerade l&#xE4;kemedel, och inkorporeringen av dessa fragment i metallkomplex f&#xF6;rv&#xE4;ntas motverka resistens p&#xE5; samma g&#xE5;ng som fragmenten ger bibeh&#xE5;llen terapeutisk effekt. Konceptet har redan visats giltigt f&#xF6;r en j&#xE4;rnf&#xF6;rening som har genomg&#xE5;tt kliniska studier, och komplex utvecklade inom detta forskningsprojekt har visat antimalaria-egenskaper. Forskningen &#xE4;r av preklinisk natur och syftar till att utveckla aktiva substanser som kan utg&#xF6;ra grund f&#xF6;r framtida l&#xE4;kemedelsutveckling.</narrative>
   <narrative xml:lang="EN">This project will focus on the preparation of organometallic metal complexes that may function as antimalarial drugs. Complex synthesis is developed in collaboration with research teams in South Africa (University of Cape Town) and India (Banaras Hindu University, Varanasi). The antimalarial properties will be tested on Plasmodium falciparum malaria parasites in collaboration with&#xA0;researchers at the University of Cape Town.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2021-01-01" type="1"></activity-date>
  <activity-date iso-date="2023-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12262" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Malaria control</narrative>
  </sector>
  <tag code="3.3" vocabulary="3">
   <narrative xml:lang="EN">3.3 - By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.</narrative>
   <narrative xml:lang="SV">3.3 - Senast 2030 utrota epidemierna av aids, tuberkulos, malaria och f&#xF6;rsummade tropiska sjukdomar samt bek&#xE4;mpa hepatit, vattenburna sjukdomar och andra smittsamma sjukdomar.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">191542.3987687859</value>
  </budget>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">196206.0884468748</value>
  </budget>
  <budget>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">116923.3639193648</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-11-24"></transaction-date>
   <value currency="USD" value-date="2020-11-24">469995.7653343757</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-01-28"></transaction-date>
   <value currency="USD" value-date="2021-01-28">191542.3987687859</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
